



NEWS RELEASE

Arcus Biosciences to Participate in Upcoming Investor Conferences

2/11/2021

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming 2021 virtual investor conferences:

- 10th Annual SVB Leerink Global Healthcare Conference, Friday, February 26 at 12:00 pm ET
- Cowen 41st Annual Health Care Conference, Tuesday, March 2 at 11:10 am ET
- Barclays Global Healthcare Conference, Wednesday, March 10 at 1:15 pm ET

A live audio webcast of each presentation will be available by visiting the "Investors" section of the Arcus website at www.arcusbio.com. A replay of each webcast will be available for at least two weeks following the live event.

About Arcus Biosciences

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: **Etrumadenant (AB928)**, the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. **AB680**, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. **Domvanalimab (AB154)**, an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1-

high metastatic non-small cell lung cancer (NSCLC) evaluating zimberelimab monotherapy, domvanalimab with zimberelimab and domvanalimab plus AB928 with zimberelimab. In addition, domvanalimab is advancing into ARC-10, Arcus's "two in one trial" to support the potential approvals of both zimberelimab and zimberelimab + domvanalimab and a registrational study, in collaboration with AstraZeneca, evaluating the curative-intent stage III NSCLC setting. **AB308**, an anti-TIGIT antibody that is FcR enabled, is advancing into clinical development to investigate additional indications, with a focus on hematological malignancies. **Zimberelimab (AB122)**, Arcus's anti-PD-1 monoclonal antibody, was in-licensed to enable the development of Arcus's combination regimens and is being evaluated in various combinations across the portfolio. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Source: Arcus Biosciences

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210211005864/en/): <https://www.businesswire.com/news/home/20210211005864/en/>

Katherine Bock

VP Investor Relations & Corporate Strategy

(510) 694-6231

kbock@arcusbio.com

Source: Arcus Biosciences, Inc.